Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Issued: 2012-2024

Historic Shares Issued for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $316.4 million.

  • Ocular Therapeutix's Shares Issued was N/A to $89.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $518.1 million, marking a year-over-year change of. This contributed to the annual value of $316.4 million for FY2024, which is 169.79% up from last year.
  • Per Ocular Therapeutix's latest filing, its Shares Issued stood at $316.4 million for FY2024, which was up 169.79% from $117.3 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Shares Issued peaked at $316.4 million during FY2024, and registered a low of $940,000 during FY2022.
  • Over the past 3 years, Ocular Therapeutix's median Shares Issued value was $117.3 million (recorded in 2023), while the average stood at $144.9 million.
  • In the last 5 years, Ocular Therapeutix's Shares Issued tumbled by 98.85% in 2021 and then soared by 12,374.57% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Shares Issued (Yearly) stood at $224.7 million in 2020, then crashed by 98.85% to $2.6 million in 2021, then tumbled by 63.65% to $940,000 in 2022, then surged by 12,374.57% to $117.3 million in 2023, then soared by 169.79% to $316.4 million in 2024.